Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2022 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the...
March 08, 2022 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it...
February 16, 2022 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan...
January 05, 2022 16:01 ET | Source: Calithera Biosciences, Inc.

Calithera to Present at the H.C. Wainwright BioConnect Virtual Conference

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan...
November 12, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera to Present at the 2021 Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan...
November 09, 2021 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights

-- Company strengthened precision oncology clinical pipeline through acquisition of mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals -- -- Cash, cash...
November 05, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial

--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat --Company will focus on advancing newly acquired targeted oncology compounds sapanisertib...
November 05, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announces the...
November 02, 2021 16:05 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the...
November 01, 2021 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 2021

-- CB-280 was well-tolerated, showed linear PK and demonstrated robust dose-related PD effects-- Encouraging trends seen in disease biomarkers including increased FeNO and decreased sweat chloride--...